MediRama Successfully Concludes "ASCO 2026 Highlights," Providing Strategic Direction for Clinical Research Through Analysis of the Latest Oncology Data

Experts have emphasized that failing to keep pace with and accurately interpret newly emerging clinical data in real time may leave even the design of a drug development pipeline outdated. Speaking at the MediRama Highlights ASCO 2026 event held on July 16 at Yuhan Corporation's headquarters in Seoul, Dr. Hanlim Moon, CEO of MediRama and a former medical oncologist at The Catholic University of Korea College of Medicine, stressed that "The landscape of global oncology drug development is evolving at an unprecedented pace. Clinical researchers must thoroughly understand the rapidly expanding body of scientific evidence to ensure that the clinical studies they design remain competitive in the global market."

Dr. Moon continued, "Without a clear understanding of the latest research and development trends, companies risk investing enormous amounts of time and resources in clinical trial designs that are no longer meaningful. In that sense, MediRama Highlights ASCO 2026 serves as an important forum for helping Korean researchers identify the right direction for future drug development."

The seminar reviewed the most influential clinical studies presented at ASCO 2026, including Plenary Session presentations and oral abstracts, while also covering the latest advances in circulating tumor DNA (ctDNA), immuno-oncology, antibody-drug conjugates (ADCs), and molecularly targeted therapies. Beyond presenting the study results, the speakers provided detailed discussions of expert commentary from the meeting, as well as the potential regulatory implications and likelihood of future approvals.

A key highlight of the seminar was Dr. Moon's expert review of the five Late-Breaking Abstracts (LBA1–LBA5) that attracted the greatest attention at this year's ASCO Annual Meeting. These studies were widely recognized as potential game changers capable of transforming the treatment landscape for difficult-to-treat cancers, including genitourinary cancers, sarcomas, lung cancer, and pancreatic cancer. Among the studies discussed was the PROTEUS trial, which evaluated apalutamide in combination with androgen deprivation therapy (ADT) before and after surgery for patients with high-risk localized prostate cancer. Dr. Moon also reviewed the LIBRETTO-432 study, which demonstrated the potential of precision medicine in the adjuvant setting, as well as the RASolute 302 trial, which produced unprecedented results in pancreatic cancer—a disease long regarded as one of the most challenging to treat.

The LIBRETTO-432 trial evaluated selpercatinib as adjuvant therapy in patients with Stage II–IIIA RET fusion-positive non-small cell lung cancer (NSCLC) following complete surgical resection. Compared with placebo, selpercatinib reduced the risk of disease recurrence or death by 82.8% (hazard ratio [HR], 0.172), demonstrating remarkable clinical efficacy.

Dr. Moon noted that the study represents a landmark example of how precision targeted therapies are rapidly moving beyond extending survival in advanced disease toward improving cure rates through early-stage adjuvant treatment. As such, the findings carry important implications for the development of future targeted therapies against similar molecular alterations.

Another major focus was the RASolute 302 study evaluating the investigational RAS inhibitor daraxonrasib, which has been regarded as a potential breakthrough for pancreatic cancer treatment. Compared with standard chemotherapy, daraxonrasib reduced the risk of death by 60% and nearly doubled median overall survival (13.2 months versus 6.6 months).

The study received widespread recognition within the oncology community because it demonstrated, for the first time, that precision medicine targeting previously intractable RAS-driven pancreatic cancer could deliver substantial and measurable clinical benefit, potentially establishing a new standard of care.

Dr. Moon concluded, "Carefully analyzing both the successes and failures of major global clinical studies provides invaluable guidance for Korean biotechnology companies. The ability to determine the appropriate patient population through biomarker selection and to define meaningful clinical endpoints ultimately determines the success or failure of drug development." She emphasized that these considerations have become increasingly critical in designing competitive oncology clinical trials.

Source : [메디칼타임즈] 급변하는 항암 개발 트랜드…알지 못하면 임상 실패한다 (Medical Times)